Table 2 Evidence of drug use from urine drug screens (UDS), at baseline and during treatment, among 39 patients who persisted with treatment for 12Â months
| Â | Month 1 | Month 3 | Month 6 | Month 12 | Baseline vs Month 3 | Baseline vs Month 12 | Month 3 vs Month 6 | Month 3 vs Month 12 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre-treatment baseline | Induction phaseb | |||||||||||||
Median number of UDS conducted (range) | 3 (2–4) | 4 (0–7) | 7 (2–10) | 7 (1–9) | 8 (1–11) | Related samples Wilcoxon signed rank test p value | ||||||||
Median % of UDS heroin negative (interquartile range) | 0 (0–0) | 0 (0–33) | 50 (0–89) | 40 (0–100) | 87 (33–100) | < 0.001 | < 0.001 | 0.86 | 0.01 | |||||
All UDS negative during period | p value from McNemar test | |||||||||||||
 Heroin | 1 | (3) | 4 | (11) | 8 | (21) | 12 | (31) | 18 | (46) | 0.04 | < 0.001 | 0.34 | 0.04 |
 Benzodiazepine | 13 | (33) | 18 | (50) | 15 | (38) | 18 | (46) | 15 | (38) | 0.77 | 0.79 | 0.45 | 1.0 |
 Cannabisa | 19/32 | (59) | 18/28 | (64) | 20/37 | (54) | 16/33 | (48) | 14/36 | (39) | 0.69 | 0.11 | 1.0 | 0.29 |
 Cocaine | 36 | (92) | 36 | (100) | 32 | (82) | 31 | (79) | 33 | (85) | 0.22 | 0.45 | 1.0 | 1.0 |
 Heroin, benzos & cocaine | 0 | (0) | 1 | (3) | 6 | (15) | 8 | (21) | 9 | (23) | n/a | n/a | 0.63 | 0.55 |